PARP Inhibitors: Recent Research Advancements in Prostate Cancer (2025–2026)
PARP inhibitors are among the most significant advances in precision medicine for prostate cancer. These drugs work by blocking DNA […]
Developing Clarity Through Research
Our 2023 Pathfinder Award winner is Dr. John Lewis, a “research rockstar” who recently pioneered a new PSA Test using AI for enhanced precision called Clarity DX. Dr. Lewis accepts his award with a talk on how prostate cancer research has changed and evolved in the 7 years since we last spoke with him.
Diagnosis, Prognosis and Therapeutic Targeting
Dr. Bismar is currently a Professor at the University of Calgary and Adjunct Professor in the Department of Oncology at McGill University. For this talk he gives us an update on the innovations and processes used to diagnose, treat and target prostate cancer cells using the most acronyms you’re likely ever to see. A lively debate follows in the Q&A section about the worth and value of PSA testing and more.